Emotional disorders associated to multiple sclerosis and psychological interventions: a literature review

1. Reich DS, Lucchinetti CF Calabresi PA,2018. Multiple Sclerosis. N. Engl. J. Med 2018; 378: 169–180.Search in Google Scholar

2. Walton C, King R, Rechtman L et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition. Mult Scler 2020;26(14):1816-1821.10.1177/1352458520970841Search in Google Scholar

3. Maier S, Bălaşa R, Buruian M, Maier A, Bajko Z. Depression in multiple sclerosis – Review. Romanian Journal of Neurology/Revista Romana de Neurologie 2015; XIV: 22-29.10.37897/RJN.2015.1.4Search in Google Scholar

4. Cerqueira AC, Andrade PS, Godoy-Barreiros JM, Silva ACO, Nardi AE. Risk factors for suicide in multiple sclerosis: a case-control study. J Bras Psiquiatr 2015;64(4):303-6.10.1590/0047-2085000000093Search in Google Scholar

5. Abreu P, Mendonça MT, Guimaraes J, Sa MJ. Esclerose múltipla: epidemiologia, fisiopatologia e diagnostico diferencial. Sinapse 2012;12(2):5e14.Search in Google Scholar

6. Hatch MN, Schaumburg CS, Lane TE, Keirstead HS. Endogenous remyelination is induced by transplant rejection in a viral model of multiple sclerosis. J Neuroimmunol 2009;212(1):74e81.10.1016/j.jneuroim.2009.05.002Search in Google Scholar

7. Atlas of MS, 3rd Edition. The Multiple Sclerosis International Federation (MSIF), London, September 2020. Available at https://www.msif.org/wp-content/uploads/2020/10/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf Accessed October 2, 2021.Search in Google Scholar

8. Smets I, Van Deun L, Bohyn C et al. Belgian Study Group for Multiple Sclerosis. Corticosteroids in the management of acute multiple sclerosis exacerbations. Acta Neurol Belg 2017;117(3):623-633.10.1007/s13760-017-0772-0Search in Google Scholar

9. Horta-Hernández AM, Esaclera-Izquierdo B, Yusta-Izquierdo A et al. High-dose oral methylprednisolone for the treatment of multiple sclerosis relapses: cost-minimisation analysis and patient’s satisfaction. Eur J Hosp Pharm 2019;26(5):280-284.10.1136/ejhpharm-2018-001499Search in Google Scholar

10. Callegari I, Derfuss T, Galli E. Update on treatment in multiple sclerosis. Presse Med. 2021;50(2):104068. doi: 10.1016/j.lpm.2021.104068.10.1016/j.lpm.2021.104068Search in Google Scholar

11. Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L. Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol 2020;19:336–47.10.1016/S1474-4422(19)30391-6Search in Google Scholar

12. van Pesch V, Sindic CJ, Ferna´ndez O. Effectiveness and safety of natalizumab in real-world clinical practice: review of observational studies. Clin Neurol Neurosurg 2016;149:55–63.10.1016/j.clineuro.2016.07.00127475049Search in Google Scholar

13. Butzkueven H, Kappos L, Wiendl H, et al. Tysabri Observational Program (TOP) Investigators. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP). J Neurol Neurosurg Psychiatry 2020;91(6):660-668.10.1136/jnnp-2019-322326727920132234967Search in Google Scholar

14. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017;376:209–20.10.1056/NEJMoa160646828002688Search in Google Scholar

15. Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol 2017;74:961–9.10.1001/jamaneurol.2017.0676571032328604916Search in Google Scholar

16. Fabis-Pedrini MJ, Carroll WM, Kermode AG. Efficacy and safety of mitoxantrone use in aggressive multiple sclerosis (P3.414). Neurology 2018;90(15):P3.414.Search in Google Scholar

17. Cohen JA, Baldassari LE, Atkins HL, et al. Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2019;25:845–54.10.1016/j.bbmt.2019.02.01430794930Search in Google Scholar

18. Bullis JR, Boettcher H, Sauer-Zavala S, Farchione TJ, Barlow DH. What is an emotional disorder? A transdiagnostic mechanistic definition with implications for assessment, treatment, and prevention. Clin Psychol Sci Pract. 2019;26:e12278.10.1111/cpsp.12278Search in Google Scholar

19. Feinstein A, Magalhaes S, Richard JF, Audet B, Moore C. The link between multiple sclerosis and depression. Nat Rev Neurol 2014;10(9):507-517.10.1038/nrneurol.2014.13925112509Search in Google Scholar

20. Butler E, Matcham F, Chalder T. A systematic review of anxiety amongst people with multiple sclerosis. Mult. Scler. Relat. Disord 2016;10 :145–168.Search in Google Scholar

21. Boeschoten RE, Braamse AMJ, Beekman ATF, et al. Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis. J Neurol Sci 2017;372:331-341.10.1016/j.jns.2016.11.06728017241Search in Google Scholar

22. Possa MF, Minacapelli E, Canale S, Comi G, Martinelli V, Falautano M. The first year after diagnosis: psychological impact on people with multiple sclerosis. Psychol Health Med 2017;22:1063-1071.10.1080/13548506.2016.127404328058855Search in Google Scholar

23. Pujol J, Bello J, Deus J, Martí-Vilalta JL, Capdevila A. Lesions in the left arcuate fasciculus region and depressive symptoms in multiple sclerosis. Neurology 1997;49:1105-1110.10.1212/WNL.49.4.11059339697Search in Google Scholar

24. Bakshi R, Czarnecki D, Shaikh ZA, et al. Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport 2000;11:1153-1158.10.1097/00001756-200004270-0000310817583Search in Google Scholar

25. Gobbi C, Rocca MA, Riccitelli G, et al. Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis. Mult Scler 2014;20:192-201.10.1177/135245851349368423812284Search in Google Scholar

26. Stuke H, Hanken K, Hirsch J, et al. Cross-sectional and longitudinal relationships between depressive symptoms and brain atrophy in MS patients. Front Hum Neurosci 2016;10:622.10.3389/fnhum.2016.00622515969728018194Search in Google Scholar

27. Minden SL, Feinstein A, Kalb RC, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014;82:174-181.10.1212/WNL.0000000000000013389743424376275Search in Google Scholar

28. Brenner P, Piehl F. Fatigue and depression in multiple sclerosis: pharmacological and non-pharmacological interventions. Acta Neurol Scand 2016;134:47-54.10.1111/ane.1264827580906Search in Google Scholar

29. Patten SB, Metz LM. Interferon beta1a and depression in secondary progressive MS: data from the SPECTRIMS Trial. Neurology 2002;59:744-746.10.1212/WNL.59.5.744Search in Google Scholar

30. Patti F, Amato MP, Trojano M, et al. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study. Mult Scler 2011;17:991-1001.10.1177/135245851140194321502310Search in Google Scholar

31. Zephir H, De Seze J, Stojkovic T, et al. Multiple sclerosis and depression: influence of interferon beta therapy. Mult Scler 2003;9(3):284-288.10.1191/1352458503ms915oa12814176Search in Google Scholar

32. Drago A, Crisafulli C, Sidoti A, Serretti A. The molecular interaction between the glutamatergic, noradrenergic, dopaminergic and serotoninergic systems informs a detailed genetic perspective on depressive phenotypes. Prog Neurobiol. 2011;94:418-60.10.1016/j.pneurobio.2011.05.00921723912Search in Google Scholar

33. Bechtholt-Gompf AJ, Walther HV, Adams MA, Carlezon WA, Öngür D, Cohen BM. Blockade of astrocytic glutamate uptake in rats induces signs of anhedonia and impaired spatial memory. Neuropsychopharmacology. 2010;35:2049–2059. doi: 10.1038/npp.2010.74.10.1038/npp.2010.74305529920531459Search in Google Scholar

34. Maier S, Buruian M, Maier A, et al. The determinants of depression in a Romanian cohort of multiple sclerosis patients. Acta Neurol Belg 2016;116:135–143.10.1007/s13760-015-0547-426442687Search in Google Scholar

35. Tauil CB, Grippe TC, Dias RM, et al. Suicidal ideation, anxiety, and depression in patients with multiple sclerosis. Arq Neuropsiquiatr 2018;76(5):296-301.10.1590/0004-282x2018003629898075Search in Google Scholar

36. McGuigan C, Hutchinson M. Unrecognised symptoms of depression in a community–based population with multiple sclerosis. J. Neurol 2006; 253 (2): 219–223.10.1007/s00415-005-0963-016177840Search in Google Scholar

37. Güner MC, Yazarb MS, Meterelliyozb KS. Cognitive predictors of depression and anxiety in individuals with newly diagnosed Multiple Sclerosis. Eur. J. Psychiat 2020;34(4):202-210.Search in Google Scholar

38. Coughlin SS, Sher L. Suicidal behavior and neurological illnesses. J Depress Anxiety 2013; 9(1):12443.Search in Google Scholar

39. Gill S, Santo J, Ph.D., Blair M, Morro SA. Depressive Symptoms Are Associated With MoreNegative Functional Outcomes Than Anxiety Symptoms in Persons With Multiple Sclerosis. J Neuropsychiatry Clin Neurosci 2019; 31:37–42.10.1176/appi.neuropsych.1801001130187820Search in Google Scholar

40. Hanna M, Strober LB. Anxiety and depression in Multiple Sclerosis (MS): Antecedents, consequences, and differential impact on well-being and quality of life. Mult Scler Relat Disord 2020;44:102261.10.1016/j.msard.2020.102261771908632585615Search in Google Scholar

41. Suh Y, Motl RW and Mohr DC. Physical activity, disability, and mood in the early stage of multiple sclerosis. Disabil Health J 2010; 3(2): 93–98.10.1016/j.dhjo.2009.09.00221122774Search in Google Scholar

42. Ayache SS, Chalah MA. Fatigue in multiple sclerosis – insights into evaluation and management? Neurophysiol Clin 2017;2017 (47):139–71.Search in Google Scholar

43. Ayache SS, Chalah MA, Kümpfel T, Padberg F, Lefaucheur JP, Palm U. Multiple sclerosis fatigue, its neural correlates, and its modulation with tDCS. Fortschr Neurol Psychiatr 2017;85:260–9.Search in Google Scholar

44. Herring TE, Alschuler KN, Knowles LM, et al. Differences in correlates of fatigue between relapsing and progressive forms of multiple sclerosis, Mult Scler Relat Disord 54:103109.10.1016/j.msard.2021.10310934237561Search in Google Scholar

45. Greeke EE, Chua AS, Healy BC, Rintell DJ, Chitnis T, Glanz BI. Depression and fatigue in patients with multiple sclerosis. J Neurol Sci. 2017 Sep 15;380:236-241.10.1016/j.jns.2017.07.04728870578Search in Google Scholar

46. Poddaa J, Ponzioa M, Uccellia MM, et al. Predictors of clinically significant anxiety in people with multiple sclerosis: A one-year follow-up study. Mult Scler Relat Disord 2020;45:102417.10.1016/j.msard.2020.10241732736214Search in Google Scholar

47. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Mult Scler 2007;13:67-72.10.1177/135245850607116117294613Search in Google Scholar

48. Wallis O, Bol Y, Köhler S, van Heugten C. Anxiety in multiple sclerosis is related to depressive symptoms and cognitive complaints. Acta Neurol Scand 2020;141(3):212-218.10.1111/ane.1319131693750Search in Google Scholar

49. Brenner P, Burkill S, Jokinen J, Hillert J, Bahmanyar S, Montgomery S. Multiple sclerosis and risk of attempted and completed suicide-a cohort study. Eur J Neurol. 2016 Aug;23(8):1329-36. doi: 10.1111/ene.13029.10.1111/ene.1302927120108Search in Google Scholar

50. Romaniuc A, Bălaşa R, Ştirbu N, et al. The Main Determinants for Suicidal Ideation in a Romanian Cohort of Multiple Sclerosis Patients. Behav Neurol. 2020;2594702.10.1155/2020/2594702720151132399081Search in Google Scholar

51. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology 2002;59:674-678.10.1212/WNL.59.5.674Search in Google Scholar

52. Lewis VM, Williams K, KoKo C, Woolmore J, Jones C, Powell T. Disability, depression and suicide ideation in people with multiple sclerosis. J Affect Disord 2017;208:662-669.10.1016/j.jad.2016.08.03827866709Search in Google Scholar

53. Shen Q, Lu H, Xie D, Wang H, Zhao Q, Xu Y. Association between suicide and multiple sclerosis: An updated meta-analysis. Mult Scler Relat Disord 2019;34:83-90.10.1016/j.msard.2019.06.01231233959Search in Google Scholar

54. Silveira C, Guedes R, Maia D, Curral R, Coelho R. Neuropsychiatric Symptoms of Multiple Sclerosis: State of the Art. Psychiatry Investig 2019;16(12):877-888.10.30773/pi.2019.0106693313931805761Search in Google Scholar

55. Stamoula E, Siafis S, Dardalas I, et al. Antidepressants on Multiple Sclerosis: A Review of In Vitro and In Vivo Models. Front Immunol 2021;12:677879.10.3389/fimmu.2021.677879817321034093579Search in Google Scholar

56. Fiest KM, Walker JR, Bernstein CN, et al. Systematic review and meta-analysis of interventions for depression and anxiety in persons with multiple sclerosis. Mult Scler Relat Disord 2016;18:96–104.10.1016/j.msard.2015.10.00426856938Search in Google Scholar

57. Politte LC, Huffman JC, Stern TA. Neuropsychiatric manifestations of multiple sclerosis. Prim Care Companion J Clin Psychiatry 2008;10(4):318-324.10.4088/PCC.v10n0408252823818787677Search in Google Scholar

58. Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging 2009;4:225-33.Search in Google Scholar

59. Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med 2015;175(3):401-7.10.1001/jamainternmed.2014.7663435875925621434Search in Google Scholar

60. Cuijpers P, Berking M, Andersson G, Quigley L, Kleiboer A, Dobson KS. A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Can J Psychiatry 2013;58(7):376-85.10.1177/07067437130580070223870719Search in Google Scholar

61. Kiropoulos L, Kilpatrick T, Kalincik T, et al. Comparison of the effectiveness of a tailored cognitive behavioural therapy with a supportive listening intervention for depression in those newly diagnosed with multiple sclerosis (the ACTION-MS trial): protocol of an assessor-blinded, active comparator, randomised controlled trial. Trials 2020; 21(1):100.10.1186/s13063-019-4018-8697186731959224Search in Google Scholar

62. Beck AT, Rush AJ, Shaw BE, Emery G. Cognitive therapy of depression. New York: Guilford Press, 1979.Search in Google Scholar

63. Ghielen I, Rutten S, Boeschoten RE, et al. The effects of cognitive behavioral and mindfulness-based therapies on psychological distress in patients with multiple sclerosis, Parkinson’s disease and Huntington’s disease: Two meta-analyses. J Psychosom Res 2019;122:43-51.10.1016/j.jpsychores.2019.05.00131126411Search in Google Scholar

64. Hind D, Cotter J, Thake A, et al. Cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: a systematic review and meta-analysis. BMC Psychiatry 2014; 14:5.10.1186/1471-244X-14-5389056524406031Search in Google Scholar

65. Ratajska A, Zurawski J, Healy B, Glanz BI. Computerized Cognitive Behavioral Therapy for Treatment of Depression in Multiple Sclerosis: A Narrative Review of Current Findings and Future Directions. Int J MS Care 2019;21(3):113-123.10.7224/1537-2073.2017-094655299131191176Search in Google Scholar

66. Huguet A, Rao S, McGrath PJ, Wozney L, Wheaton M, Conrod J, Rozario S. A Systematic Review of Cognitive Behavioral Therapy and Behavioral Activation Apps for Depression. PLoS One 2016; 11(5):e0154248.10.1371/journal.pone.0154248485292027135410Search in Google Scholar

67. Hayter AL, Salkovskis PM, Silber E, Morris RG. The impact of health anxiety in patients with relapsing remitting multiple sclerosis: Misperception, misattribution and quality of life. Br J Clin Psychol 2016;55(4):371-386.10.1111/bjc.1210626806805Search in Google Scholar

68. Chalah MA, Ayache SS. Cognitive behavioral therapies and multiple sclerosis fatigue: A review of literature. J Clin Neurosci 2018;52:1-4.10.1016/j.jocn.2018.03.02429609859Search in Google Scholar

69. van den Akker LE, Beckerman H, Collette EH, et al. TREFAMS-ACE Study Group. Cognitive behavioral therapy positively affects fatigue in patients with multiple sclerosis: Results of a randomized controlled trial. Mult Scler 2017;23(11):1542-1553.10.1177/135245851770936128528567Search in Google Scholar

70. Gromisch ES, Kerns RD, Beauvais J. Pain-related illness intrusiveness is associated with lower activity engagement among persons with multiple sclerosis. Mult Scler Relat Disord 2020;38:101882.10.1016/j.msard.2019.10188231812040Search in Google Scholar

71. Abbasi S, Alimohammadi N, Pahlavanzadeh S. Effectiveness of cognitive behavioral therapy on the quality of sleep in women with multiple sclerosis: a randomized controlled trial study. Int J Community Based Nurs Midwifery 2016;4:320–8.Search in Google Scholar

72. Calandri E, Graziano F, Borghi M, Bonino S. Improving the quality of life and psychological well-being of recently diagnosed multiple sclerosis patients: preliminary evaluation of a group-based cognitive behavioral intervention. Disabil Rehabil 2016;1–8.10.1080/09638288.2016.119843027385055Search in Google Scholar

73. Mohr DC, Cox D, Merluzzi N. Self-Injection Anxiety Training: a treatment for patients unable to self-inject injectable medications. Mult. Scler 2005;11(2):182-185.10.1191/1352458505ms1146oa15794392Search in Google Scholar

74. Topcu G, Griffiths H, Bale C, et al. Psychosocial adjustment to multiple sclerosis diagnosis: A meta-review of systematic reviews. Clin Psychol Rev 2020; 82: 101923,10.1016/j.cpr.2020.10192332992071Search in Google Scholar

75. Hofmann SG, Hayes SC. The Future of Intervention Science: Process-Based Therapy. Clin Psychol Sci. 2019;7(1):37-50.10.1177/2167702618772296635052030713811Search in Google Scholar

76. David D, Schnur J, Belloiu, A. Another Search for the “Hot” Cognitions: Appraisal, Irrational Beliefs, Attributions, and Their Relation to Emotion. J Ration Emot Cogn Behav Ther 2002; 20(2): 93–131.10.1023/A:1019876601693Search in Google Scholar

77. Ellis A. Changing rational-emotive therapy (RET) to rational emotive behavior therapy (REBT). J Ration Emot Cogn Behav Ther 1995;13(2): 85–89.10.1007/BF02354453Search in Google Scholar

78. David D, Cotet C, Matu S, Mogoase C, Stefan S. 50 years of rational emotive and cognitive-behavioral therapy: A systematic review and meta-analysis. J. Clin. Psychol 2018; 74(3): 304–318.Search in Google Scholar

79. Popa CO, Predatu R. The effect of an integrative CBT/REBT intervention in improving emotional functioning and emotional stability in Romanian medical students. J Evid-Base Psychot 2019;19(1):59-72.10.24193/jebp.2019.1.4Search in Google Scholar

80. Maggio MG, Cuzzola MF, Latella D, et al. How personality traits affect functional outcomes in patients with multiple sclerosis: A scoping review on a poorly understood topic. Mult Scler Relat Disord 2020;46.10.1016/j.msard.2020.10256033049463Search in Google Scholar